ABSTRACT: Deep vein thrombosis and pulmonary embolism (PE) prove venous embolic activity and enforce the suspicion of paradoxical embolism in patients with stroke with patent foramen ovale. Because it has implications in secondary prevention, we investigated the frequency of silent PE in such a cohort of patients.
Patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale who underwent a ventilation perfusion scintigraphy were identified from a stroke registry. Blinded from clinical data, ventilation perfusion scintigraphy scans were re-evaluated independently by 2 experts. Patients showing at least a subsegmental defect were considered as having silent PE. Factors potentially associated with PE were analyzed.
The evaluation included 151 patients. Median age was 55.2 years and 59.9% were male. In 56 (37%) patients, silent PE was found; a deep vein thrombosis was evident in 11 (7%) patients. Atrial septal aneurysm was identified in 39 patients and hypermobile atrial septum in 37 patients. Atrial septal aneurysm and hypermobile atrial septum were independently associated with PE. In females, intake of oral contraceptives showed certain association with PE (6 of 25 versus 3 of 40; P=0.07).
Silent PE frequently occurs in patients with cryptogenic stroke and patent foramen ovale, particularly when atrial septal aneurysm or hypermobile atrial septum are present.
Stroke 03/2011; 42(3):822-4. · 5.73 Impact Factor
ABSTRACT: 133Xe has been widely used for measuring blood flow in various organs. Because an injectable solution of 133Xe is not commercially available, a technique is presented that allows both the production of the radiopharmaceutical and the drawing of individualized patient doses.
A system was designed to crush ampoules of 133Xe gas inside a sealed cylinder containing sodium chloride injection 0.9%.
133Xe ampoules of different sizes and filled with different activities were crushed within the system. The steel cylinder shielded 98% of the radiation. With 34 GBq 133Xe a total of 20 studies of cerebral blood flow were performed. No bacteriological contamination of the drawn doses was detected.
The crusher system allows the efficient and safe production of an injectable solution of 133Xe with sodium chloride 0.9%.
Nuclear Medicine Communications 05/2007; 28(4):327-9. · 1.40 Impact Factor
Clinical Nuclear Medicine 03/2003; 28(2):136-7. · 3.67 Impact Factor